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Background: Viewed in terms of input and output, the mechanisms of depression are still akin to a black box.
However, there must be main pivots for diverse types of depression. From recent therapeutic observations, both
the serotonin (5-HT) and kynurenine pathways of tryptophan metabolism may be of particular importance to
improved understanding of depression. Here, I propose an etiological classification of depression, based on key
peripheral and central enzymes of tryptophan metabolism.
Discussion: Endogenous depression is caused by a larger genetic component than reactive depression. Besides
enterochromaffin and mast cells, tryptophan hydroxylase 1 (TPH1), primarily expressed in the gastrointestinal tract, is
also found in 5-hydroxytryptophan-producing cells (5-HTP cells) in normal intestinal enterocytes, which are thought to
essentially shunt 5-HT production in 5-HT-producing cells. Genetic studies have reported an association between TPH1
and depression, or the responsiveness of depression to antidepressive medication. Therefore, it is possible that
hypofunctional 5-HTP cells (reflecting TPH1 dysfunction) in the periphery lead to deficient brain 5-HT levels. Additionally,
it has been reported that higher TPH2 expression in depressed suicides may reflect a homeostatic response to deficient
5-HT levels. Subsequently, endogenous depression may be caused by TPH1 dysfunction combined with compensatory
TPH2 activation. Reactive depression results from life stresses and involves the hypothalamic-pituitary-adrenal axis, with
resulting cortisol production inducing tryptophan 2,3-dioxygenase (TDO) activation. In secondary depression, caused by
inflammation, infection, or oxidative stress, indoleamine 2,3-dioxygenase (IDO) is activated. In both reactive and
secondary depression, the balance between 3-hydroxykynurenine (3-HK) and kynurenic acid may shift towards 3-HK
production via kynurenine-3-monooxygenase (KMO) activation. By shifting the equilibrium position of key enzymes of
tryptophan metabolism, the classical classification of depression can be reorganized, as below.




Central classification of depression by key enzymes
 TPH2 activation
 KMO activation
Summary: Etiological classification of depression expressed by peripheral (TPH1, TDO, IDO) and central (TPH2, KMO)
enzymes of tryptophan metabolism may enable depression to be viewed as a clear box, with the inner components
available for inspection and treatment.
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Historical classification of depression into “reactive” (or
“exogenous”) and “endogenous” forms has produced no
remarkable progress in its clinical picture or long-term
outcome. This may be because of dynamic reciprocal
interaction between life events and the genesis of de-
pression, which can be observed from sociological, psy-
chological or biological points of view [1,2].
Even though depression is characterized as an episodic
illness, prospective studies have found that recurrence is
the norm rather than the exception [3-5].
Furthermore, consistent evidence supports a “kindling
hypothesis”, in which depressive episodes are more easily
triggered over time, as a process that occurs by lowering
the impact threshold for stressful life events (i.e., sensi-
tization to minor events) or by increasing spontaneous
dysregulation, both indicating progressive effects of de-
pression [6-8]. Analysis of recurrence risk in a large twin
study also suggested a genetic contribution, as patients
with high genetic risk are “prekindled”, and show lower
association between stressful life events and onset of de-
pressive episodes compared with patients of low genetic
risk [9].
It has been reported that an imbalance between gluco-
corticoid and mineralocorticoid receptors in depression,
along with high-density glucocorticoid receptors, may
contribute to hippocampal susceptibility to neuronal
damage [10-12]. Subsequent hippocampal atrophy may
result in further neuroendocrine dysfunction that in-
cludes the hypothalamic-pituitary-adrenal axis (HTPA
axis) [13].
As a result of elevated glucocorticoids and compromised
hippocampal functioning, downregulation of glucocortic-
oid receptor sensitivity may occur and further perpetuate
metabolic and neuroendocrine disruption [14-16].
In these biological processes, stress and genetic vulner-
ability elevate glucocorticoid steroids and alter cellular
plasticity via downregulation of growth factors and re-
ceptor sensitivity [17]. Reduction in growth factors, such
as brain-derived neurotrophic factor (BNDF), impacts
negatively upon structural and functional processes
within the limbic system, especially the hippocampus.
Chronic and recurrent depression may result in subse-
quent atrophy and further disruptions in neurocircuitry.
In 1980, DSM-III revisions created a new taxonomy of
depression, and rather than exogenous and endogenous,
depression was classified as “major” or “minor”, with no
reference to etiology and only the diagnostic modifier
“melancholic features” (despite inconsistent inter-rater
reliabilities between melancholic and non-melancholic
features) [18].
Nowadays, clinical psychiatry approaches depression
as a cluster of maladaptive thoughts and behaviors re-
quiring corrective treatment, without consideration ofthe heterogeneity and etiological complexity of the dis-
ease. Classification of depression is controversial, caus-
ing much debate among psychiatrists, as diagnoses are
based on the presence of certain arbitrarily defined
symptoms [19-22]. Different types of depression will
have distinct causes and outcomes, and respond differ-
ently to treatment. At present, the biological mecha-
nisms of depression are still akin to a black box, viewed
merely in terms of input and output. However, there
must be main pivots for diverse types of depression.
The effects of antidepressant treatment on the sero-
tonin (5-HT) system may be intimately related to their
therapeutic effect in major depression. As identified in
the landmark Sequenced Treatment Alternatives to Re-
lieve Depression (STAR*D) study, up to one-third of
people with major depression do not respond to mul-
tiple antidepressant treatment attempts [23]. Conversely,
the effect of the NMDA receptor antagonist, ketamine,
on treatment-resistant depression appears both quick
and substantial. Kynurenic acid (KYNA) is an endogen-
ous tryptophan-derived compound that also blocks
NMDA receptors. In the trial of Murrough et al., more
drug-refractory patients responded to ketamine than the
benzodiazepine midazolam [24]. However, approximately
half of those who responded to ketamine relapsed over
the next week. The antidepressant properties of the non-
competitive NMDA receptor antagonist, MK-801 (dizocil-
pine), and the competitive NMDA receptor antagonist,
CGP 37849 (DL-(E)-2-amino-4-methyl-5-phosphono-3-
pentonoic acid) and its (R)-enantiomer CGP 40116, were
studied in a chronic mild stress model of depression by
Papp and Moryl [25]. In the study, animals were subjected
to a variety of mild stressors for prolonged periods of time,
showing substantially decreased consumption of palatable
sucrose solution (anhedonia). They also found using this
model that the stress-induced deficit in sucrose intake was
gradually reversed by treatment with these NMDA recep-
tor antagonists. The magnitude of the effect and its time
course are comparable to that following similar adminis-
tration of imipramine. Increased sucrose intake following
chronic administration of imipramine and NMDA recep-
tor antagonists is specific to stressed animals. Li et al. used
a rat 21-day chronic unpredictable stress model to test the
rapid action of NMDA receptor antagonists on depressant-
like behavior. They found that chronic unpredictable stress
exposure decreases expression levels of synaptic proteins,
spine number, and frequency and amplitude of synaptic
currents (excitatory postsynaptic currents) in layer V pyr-
amidal neurons of the prefrontal cortex, and these deficits
are rapidly reversed by ketamine [26]. Overall, these find-
ings suggest that NMDA receptor antagonists may have
antidepressant properties. Moreover, several lines of evi-
dence indicate that chronic stress and BNDF downregu-
lation are key components of depression pathology.
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strates that chronic stress impairs BNDF expression,
and both antidepressant drugs effecting the 5-HT sys-
tem and NMDA receptor antagonists correlate with in-
creased BDNF synthesis and activity [27,28]. These
observations suggest that both the 5-HT and kynurenine
pathways of tryptophan metabolism may be of particu-
lar value to better understanding depression. Here, I
propose an etiological classification of depression based
on key peripheral and central enzymes of tryptophan
metabolism.
Discussion
The first step in reclassifying depression must consider
the historical classification (including exogenous and en-
dogenous depression), despite the lack of any outstand-
ing differences between dynamic and mixed depressive
states in terms of clinical picture and long-term out-
come. Then, a new classification of depression can be
considered by restructuring the historical classification.
Depression can be classified into two new forms using
tryptophan metabolism: peripheral classification by key
enzymes, or central classification by key enzymes.
Classical etiological classification of depression
First, it is important to consider the physiological condi-
tions vulnerable to depression.
Tryptophan is an essential amino acid obtained from
dietary sources. Central tryptophan availability mainly
depends on competition by large amino acids for trans-
port across the blood–brain barrier (BBB). A large body
of evidence supports association of exercise with in-
creased plasma tryptophan and decreased plasma levels
of the branched chain amino acids (BCAAs), leucine,
isoleucine, and valine [29-33]. BCAAs inhibit tryptophan
transport into the brain, therefore increased plasma
tryptophan and decreased BCAAs cause a substantial in-
crease in tryptophan availability to the brain. Patients
with diets poor in tryptophan may be vulnerable to de-
pression, as this essential amino acid is not naturally
abundant, even in protein-rich foods. Moreover, individ-
uals with sarcopenia or who do not exercise are also vul-
nerable to depression.
In the following section, I discuss the classical etio-
logical classification of depression with potential involve-
ment of tryptophan metabolism.
 Endogenous depression
“Endogenous” (occurs from within) implies there is no
discernible cause for the depression, and it is caused by
a larger genetic component than reactive depression.
This form of depression is characterized by a high pro-
portion of biological symptoms (sleep and appetitedisturbance, poor concentration and memory, loss of
interest in sex).
Tryptophan metabolism can account for the etiology of this
depressive state:
Two isoforms of tryptophan hydroxylase (TPH) have
been discovered: TPH1, primarily expressed in the gas-
trointestinal tract, and TPH2, expressed exclusively in
neuronal cells. Excluding the brain, large amounts of 5-
HT are produced in enterochromaffin (EC) and mast
cells, and stored in platelets. TPH1 expression was
expected to be confined to EC and mast cells in the
intestine. Unexpectedly, TPH1 was also found in 5-
hydroxytryptophan-producing cells (5-HTP cells) in
normal enterocytes lining the small intestine epithe-
lium. 5-HTP cells are differentiated mucosal villous
epithelial cells, expressing positive TPH1 staining without
5-HT immunoreactivity, and secreting intermediate 5-
HTP into the mesenteric vein circulation, as stored 5-HT
is not identified within them [34-36]. 5-HTP is regarded
as a precursor of 5-HT, and 5-HTP cells are essentially
thought to shunt 5-HT production in 5-HT-producing
cells (5-HT cells), in both the periphery and brain.
TPH1 is associated with depression or the responsive-
ness of depression to antidepressive medication, by a
considerable number of genetic studies [37-42]. There
are two cellular locations for TPH1 dysfunction related
to genetic studies: TPH1 dysfunction in EC and mast
cells, or 5-HTP cells. If TPH1 dysfunction occurs in EC
and mast cells, it may lead to decreased peripheral 5-
HT, which cannot cross the BBB, therefore this situation
is unlikely to be connected to 5-HT depletion in the
brain. Consequently, TPH1 dysfunction in 5-HTP cells
should be exclusively considered. Owing to its ability to
ameliorate 5-HT depletion, 5-HTP is better than a pla-
cebo at alleviating depression [43]. Peripheral 5-HTP
cells provide an endogenous substrate for L-aromatic
amino acid decarboxylase in 5-HT cells, and it is pos-
sible that hypofunctional 5-HTP cells (reflecting TPH1
dysfunction) in the periphery lead to deficient brain 5-
HT levels, and may be a factor for depression. Hyper-
function of 5-HTP cells may have the opposite effect,
but hypofunction as a cause of pathology tends to be
more common than hyperfunction. For example, the
thyroid gland exhibits both hypothyroidism and hyper-
thyroidism, although the mean incidence of spontaneous
hypothyroidism is greater than hyperthyroidism [44].
Conversely, there are also TPH2 abnormalities in
depression. Bach-Mizrachi et al. reported that higher
TPH2 expression in depressed suicides may reflect a
homeostatic response to deficient brain 5-HT levels [45].
The genetic influence may decrease relatively if there is
abundant tryptophan supply to the brain. It is possible that
hypofunctional 5-HTP cells (reflecting TPH1 dysfunction)
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and concomitant compensatory TPH2 activation in the
brain, may cause endogenous depression.
 Reactive depression
 Secondary depression
“Reactive” implies the depression results from external
stress occurring in the sufferer’s life. The risk of this type
of depression is influenced more by the severity of life
stresses than inherited factors. Symptoms are typified
by worry and anxiety, and problems getting to sleep
(rather than waking early in the morning, as in en-
dogenous depression). It was originally argued that pa-
tients with reactive depression were less likely to
respond to antidepressants.
In secondary depression, the depression is caused by a
medical condition. One-third of patients with depression
show elevated peripheral inflammatory biomarkers, even
in the absence of a medical illness, and inflammatory ill-
nesses are associated with greater rates of depression,
suggesting inflammation is linked to depression [46].
Tryptophan metabolism can account for the etiology of
these depressive states:
Reactive depression is related to dysregulation of the
HTPA axis, a major component of the neuroendocrine
system that controls stress reactions and regulates many
body processes, mood and emotions, sexuality, and also
energy storage. The HTPA axis is the node for interactions
between the glands, hormones, and midbrain structures
involved in the general adaptation syndrome. Cortisol pro-
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Figure 1 Impaired glial-neuronal network. Impaired glial-neuronal netw
metabolism. Hypofunctional peripheral 5-HTP cells (reflecting TPH1 dysfunc
5-HT levels. In major depression, neurotoxic kynurenine metabolites (e.g., 3
with compensatory TPH2 activation, may induce astrocytic and neuronal apdioxygenase (TDO) in the liver, thus increasing kynure-
nine synthesis [47-49] (Figure 1).
In secondary depression, inflammation, infection, or oxi-
dative stress activate indoleamine 2,3-dioxygenase (IDO)
in extrahepatic tissues, including the lungs, kidneys,
spleen, blood, and brain [50,51], shifting tryptophan me-
tabolism away from the liver [52]. Consequently, trypto-
phan breakdown through the kynurenine pathway occurs
mainly in the blood and lymphoid tissues [53]. Because
liver cell uptake of extrahepatic kynurenine is not efficient,
metabolism mainly occurs extrahepatically. A key enzyme
of the kynurenine pathway, IDO, and kynurenine-3-
monooxygenase (KMO) that catalyzes 3-hydroxykynurenine
(3-HK) production, are activated by proinflammatory cy-
tokines including interleukin-1 and -6, tumor necrosis
factor-α, and interferon-γ.
In both these depressive states, the brain kynurenine
pathway is strongly activated from central and also periph-
eral kynurenine sources, as kynurenine can be transported
across the BBB. In the brain, tryptophan catabolism occurs
mainly in astrocytes and microglia [54-56]. Although some
neurons also contain IDO and/or TDO [57], neurons are
not the main sites of the kynurenine pathway within the
brain. Neuroprotective KYNA and neurotoxic 3-HK are
two intermediate metabolites of kynurenine. While astro-
cytes mainly produce KYNA because of a lack of the
KMO enzyme, microglia and macrophages produce
mainly the neurotoxin quinolinic acid (QUIN) from the 3-
HK pathway [58-60], therefore the balance between 3-HK
and KYNA may generally shift towards 3-HK and down-
stream neurotoxin production. It is possible that KMO ac-
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tion) cause a reduction in 5-HTP levels that lead to a reduction in brain
-HK and QUIN derived from 3-HK) and/or TPH1 dysfunction combined
optosis.
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derived from 3-HK in the anterior midcingulate cortex
and subgenual anterior cingulate cortex, may directly con-
tribute to disturbed balance in glutamatergic throughput,
potentially explaining the rapid response of severe depres-
sion to infusion of NMDA antagonists (e.g., ketamine)
[61]. In major depression, there is evidence of neurode-
generative changes and loss of astrocytes. Neurotoxic
kynurenine metabolites, such as 3-HK and QUIN, may
induce astrocytic and neuronal apoptosis, weakening the
glial-neuronal network responsible for induction of
astrocytic neurotrophic factor synthesis, e.g., glial-derived
neurotrophic factor (GDNF) and BDNF [62].
By shifting the equilibrium position of key enzymes in
tryptophan metabolism (as described above), the classical
depression classification can be reorganized as below:




Central classification of depression by key enzymes
 TPH2 activation
 KMO activation
Among these key enzymes, only TPH2 activation (led
by feedback from 5-HT depletion) provides alleviation
from depression, partially compensated for by 5-HT syn-
thesis. Enhanced tryptophan breakdown and further me-
tabolism via the kynurenine pathway by both TDO and
IDO, induces low tryptophan availability for 5-HT syn-
thesis in the brain, further accelerating feedback of
TPH2 activation. Conversely, TPH1 dysfunction, TDO
activation, IDO activation, and KMO activation all ex-
acerbate the depressive situation (Figure 1).
Metabolic depression and cybernetics
Metabolic depression, an adaptive biological process for
energy preservation, is responsible for dormancy, torpor,
hibernation, and estivation in animals [63]. From this
point, depression in humans may be a purposive survival
strategy, evident under threat of a metabolic energy crisis,
and easily considered the default metabolic state until con-
ditions improve following metabolic up-regulation as en-
ergy availability increases. A form of metabolic depression
is assumed in the underlying observed hypometabolism,
state-dependent neurobiological changes, and vegetative
symptoms of major depression in humans. Metabolic de-
pression is reactivated via differential gene expression in
response to perceived adverse stimuli in predisposed indi-
viduals. The cellular (micro)environment in which thegene resides dominates the status quo. Consequential dor-
mancy and major depression are characterized by with-
drawal from the environment, lack of energy, loss of
weight (from not eating and burning stored fat), and
changes in sleep patterns. It is apparently not purposive
for depressed patients to maintain or raise the metabolic
rate to cope with decreased 5-HT precursor, the severity
of life stresses, and a chronic inflammation state, hence
they suppress metabolism and remain in torpor until con-
ditions improve. There are considerations for the natural
course of depression. Nowadays, it would not be permitted
ethically to observe depressed patients without antidepres-
sant treatment for an extended period of time. However,
from a historical perspective, in 1921 before the discovery
of antidepressants, Kraepelin speculated that in most
cases, major depressive episodes tend to last about 6–8
months without treatment [64]. In short-term and mild
depression, the depressive process is adaptive and rational,
preventing other intestinal disturbances, life event
stressors, and inflammations, by withdrawing from group
activities due to depressed mood and/or loss of interest.
However, in chronic and/or severe depression, the process
may trigger a life-threatening pathological condition (e.g.,
impaired glial-neural network, thoughts of death or sui-
cide, suicide plan, losing a job).
Norbert Wiener defined cybernetics from a Greek
word meaning “the art of steering”, as “the scientific
study of control and communication in the animal and
the machine” [65]. It is applicable when a system is in-
volved in a closed signaling loop, i.e., action by the sys-
tem generates an environmental change that is reflected
in the system in some manner (feedback), triggering a
system change. Originally, this was referred to as a “cir-
cular causal” relationship. In applying the idea of cyber-
netics to depression, it is necessary to define and
integrate the functions and processes of the depressive
condition using key enzymes that can move from the en-
vironment to desired conditions or treatments.
The primary pivots steering the course of depression
may be key enzymes involved in tryptophan metabolism.
Potentially, all types of depression can be expressed
through combinations of these key enzymes using a
matrix with peripheral (TPH1, TDO, IDO) and central
(TPH2, KMO) determinants. Moreover, this classification
is not mutually exclusive, but adaptable and cumulative
based on enzyme malfunction. For example, hypothetic-
ally, if a patient with endogenous depression was severely
burned and his/her house burnt to ashes, losing all his/her
fortune, this depressive condition could be expressed as a
set of depressive states, incorporating peripheral (TPH1
dysfunction, TDO activation, IDO activation) and central
(TPH2 activation, KMO activation) determinants.
From a therapeutic point of view, it is important to reset
the shifting equilibrium position to a natural, balanced
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of depression may include gene therapy to rescue intes-
tinal 5-HTP cells or enhance peripheral 5-HTP produc-
tion and thereby compensate for TPH1 dysfunction,
psychotherapy for TDO activation, and anti-inflammatory
drugs for IDO activation. A goal of cybernetics for depres-
sion is steering key enzyme equilibrium positions to re-
cover neutral metabolic conditions.
Comorbid medical/psychiatric conditions
A matrix with peripheral (TPH1, TDO, IDO) and central
(TPH2, KMO) determinants may be considered the sta-
tus quo for various comorbid medical/psychiatric condi-
tions. For example, Cushing’s disease (in which the
pituitary gland produces pathologically high ACTH
levels, with ACTH signaling to the adrenal glands in-
creasing cortisol production) and Cushing syndrome
(caused by overuse of corticosteroid medications), in-
crease vulnerability to depression because of peripheral
TDO activation by cortisol. Conversely, drugs that sup-
press cortisol (e.g., cyproheptadine, sodium valproate,
and bromocriptine) manage depressive states caused by
peripheral TDO activation [66]. Patients with Crohn’s
disease are often affected by depression. Crohn’s disease
(also known as regional enteritis) is a type of inflamma-
tory bowel disease that affects any part of the gastro-
intestinal tract from the mouth to the anus, and may be
expressed as peripheral TPH1 dysfunction and IDO acti-
vation, induced by intestinal inflammation. Isoniazid is
an organic compound that is the first-line medication
for tuberculosis, and also a weak monoamine oxidase
(MAO) inhibitor. The era of antidepressants started with
this drug, which was accidentally found to have euphoric
effects in patients with tuberculosis. Using this matrix,
the effect of isoniazid may be expressed by IDO suppres-
sion (owing to reduced inflammation), central TPH2
suppression (via the MAO inhibitory effect, leading to
negative feedback at the rate-limiting TPH2 step), and
KMO suppression (owing to reduced inflammation, con-
comitant with IDO suppression). In this manner, the
matrix of peripheral (TPH1, TDO, IDO) and central
(TPH2, KMO) determinants can encompass comorbid
medical/psychiatric conditions with a variety of symp-
toms and be a tool for thought experiments.
Testing the hypothesis
The technology to directly measure enzyme activity
has not yet been developed, and the following experi-
mental approaches are essential to empirically test TPH1
activities.
 Collecting (through biopsy or autopsy) and
comparing intestinal 5-HTP cells from patients with
major depression and a normal control group. Monitoring serum and urinary 5-HTP will be useful
to match levels to different phases of major
depression.
The second study will assume compensatory TPH2 ac-
tivities for major depression through cerebrospinal fluid
(CSF) levels of the 5-HT metabolite, 5-hydroxyindoleacetic
acid.
The following experimental approaches are essential to
empirically test TDO and IDO activities.
 Observing relative increases in plasma or salivary
cortisol, and cytokine levels induced by
inflammation, and determining the effect on
subsequent depression development.
The second study will assume KMO activities for
major depression through CSF QUIN levels.
To test this classification, it is necessary to further
analyze genetic and enzymatic involvement, and examine
consistency in diverse mental disorders. This classification
can be regarded as provisional until it has been verified or
disproved by satisfactory evidence of changes in metabo-
lites, or ratios between metabolites, as biomarkers. If
contradictory classifications are reported, this classification
will be rejected.
Summary
The linked tryptophan–5-HT and tryptophan–kynurenine
pathways represent a major junction between gene-
environment interactions. The described etiological classi-
fication expressed by peripheral (TPH1, TDO, IDO) and
central (TPH2, KMO) enzymes allows depression to be
viewed as a clear box with the inner components, or logic,
available for appropriate individualized inspection and
treatment.
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